The FDA will permanently incorporate some of the changes it made to its procedures and policies during the COVID-19 pandemic, commissioner Stephen Hahn said in a June 1 news conference.
Hahn said the changes the agency will keep include a greater focus on decentralized clinical trials, ramping up laboratory-developed tests and increasing the use of telemedicine technology.
The FDA said it also is pivoting toward the use of real-world evidence to monitor medical products amid the pandemic.